Bristol Myers Squibb· @bmsnews · X·· 2026-05-08精选AI 评分60
AI 导读
百时美施贵宝宣布，其口服疗法获欧盟委员会批准，用于治疗对既往改善病情抗风湿药应答不足或不耐受的活动性银屑病关节炎成人患者。该批准针对的是既往治疗应答不足或不耐受的成人患者群体。
推荐理由
原文给出欧盟获批的口服疗法与适用人群，读者可据此了解银屑病关节炎口服治疗的新选项。
正文
#MEDIA: Today, we announced European Commission approval of our oral treatment for adults living with active psoriatic arthritis (PsA) who have had an inadequate response or have been intolerant to prior disease-modifying antirheumatic therapy. Read more: https://bit.ly/4tjEK8X
来源：Bristol Myers Squibb · x.com